Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

Abstract: This invention relates to the use of certain cyclic guanosine 3?,5?-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension.

Abstract: A vertical centrifugal pump unit, in particular for wet installation in a closed container, including an intermediate pipe (17) which surrounds the shaft (3) of the pump unit and is arranged between the housing (11) of the centrifugal pump (12) and a bracket (5) which carries the electric motor (1) of the unit. The pump unit preferably is fastened in particular to a horizontal flat part (19) arranged beneath the flange (6) of the bracket (5), especially the cover of a container. Production is simplified and it is possible to readily adapt the intermediate pipe to different sizes by designing the intermediate pipe (17) without a flange or other enlargements on its end faces, and pressing the end faces against the bracket (5) and the pump housing (11) using screw connections (18, 20) distributed uniformly around the circumference. The bracket (5) and the flat part (19) arranged beneath the bracket are joined together by the screw connections (18, 20).

Abstract: This invention relates to the use of certain cyclic guanosine 3?,5?-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension.

Abstract: A fastening arrangement of a machine base (8) of a machine on foundations (1). The fastening arrangement includes a foundation recess (3), filled with concrete (71, 72) and having an inner anchor shank (4), a foundation plate (2) of steel on the foundation (1), the machine base (8) on the foundation plate (2), an anti-fatigue bolt/stud bolt (9) restraining the machine against the foundation (1), the anti-fatigue bolt/stud bolt (9) being screwed into the anchor shank (4). The anchor shank (4) has at least two threaded disks (5) arranged offset from one another. The anti-fatigue bolt/stud bolt (9) screwed into the anchor shank (4) is passed through the foundation plate (2) and the machine base (8).

Abstract: A method for delivering and processing a formaldehyde-free resin at a facility. The method maintains the resin slurry at a minimum temperature throughout storage of the resin slurry and use of the resin slurry to prepare a binder composition at a make up site. Maintaining the resin slurry at or above a minimum temperature ensures that a minimum viscosity is maintained to permit the proper flow of the resin slurry. The method utilizes external heat sources in conjunction with storage and transport systems to ensure that a minimum temperature is maintained.

Abstract: A system for controlling the pH of the process water used in conjunction with formaldehyde-free binder composition for glass fiber products. A base solution is introduced into the process water used to coat the glass fibers in the formaldehyde-free binder after the water is extracted from binder coated glass fibers when the pH of the process water in less than about 6.0. The addition of the base solution increases the pH of the process water to a range from about 8.0 to about 6.0 thereby reducing the risk of corrosion when the process water is recirculated.

Abstract: A system for controlling the pH of a formaldehyde-free aqueous binder composition used in the manufacture of glass fiber products. Following the formation of an aqueous binder composition, acid is added to the composition to reduce the pH to less than about 3.4. After the acid is combined with the aqueous binder composition, the pH of the composition is measured and then compared within a pre-set set point. The rate of acid addition is then adjusted thereby adjusting the pH of the composition such that the measured pH equals the set point pH. The pH measurement is preferably done before the addition of other additives to avoid interference by those additives.

Abstract: A vertical centrifugal pump unit, in particular for wet installation in a closed container, including an intermediate pipe (17) which surrounds the shaft (3) of the pump unit and is arranged between the housing (11) of the centrifugal pump (12) and a bracket (5) which carries the electric motor (1) of the unit. The pump unit preferably is fastened in particular to a horizontal flat part (19) arranged beneath the flange (6) of the bracket (5), especially the cover of a container. Production is simplified and it is possible to readily adapt the intermediate pipe to different sizes by designing the intermediate pipe (17) without a flange or other enlargements on its end faces, and pressing the end faces against the bracket (5) and the pump housing (11) using screw connections (18, 20) distributed uniformly around the circumference. The bracket (5) and the flat part (19) arranged beneath the bracket are joined together by the screw connections (18, 20).

Abstract: A fastening arrangement of a machine base (8) of a machine on foundations (1). The fastening arrangement includes a foundation recess (3), filled with concrete (71, 72) and having an inner anchor shank (4), a foundation plate (2) of steel on the foundation (1), the machine base (8) on the foundation plate (2), an anti-fatigue bolt/stud bolt (9) restraining the machine against the foundation (1), the anti-fatigue bolt/stud bolt (9) being screwed into the anchor shank (4). The anchor shank (4) has at least two threaded disks (5) arranged offset from one another. The anti-fatigue bolt/stud bolt (9) screwed into the anchor shank (4) is passed through the foundation plate (2) and the machine base (8).

Abstract: A long-acting antiparasitic formulation suitable for topical application including: (a) 0.1-50% w/v an avermectin or milbemycin having activity against endo- and/or ectoparasites; (b) 1-50% v/v a di(C2-4 glycol) mono(C1-4 alkyl) ether; (c) an optional antioxidant; and (d) an optional skin acceptable volatile solvent q.s. v/v.